Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Host cell surface glycans and proteins represent a diverse array of molecules, including glycoproteins, glycolipids, and proteoglycans, that form the glycocalyx and mediate essential cellular interactions (Varki A, et al., Essentials of Glycobiology, 2015). These components serve as critical attachment factors and entry receptors for a wide range of pathogens, including viruses, bacteria, and toxins, which exploit specific molecular signatures to initiate infection (Maginnis MS, J Mol Biol, 2018). For instance, influenza viruses utilize hemagglutinin to bind sialic acid residues on host glycoproteins, while HIV-1 targets the CD4 protein and chemokine co-receptors (Sieben C, et al., J Gen Virol, 2014). Beyond infectious disease, alterations in host cell surface glycosylation are hallmarks of cancer progression and metastasis, influencing cell signaling and immune evasion (Pinho SS & Reis CA, Nat Rev Cancer, 2015). Therapeutic strategies targeting these molecules include the use of monoclonal antibodies, decoy receptors, and small molecule inhibitors designed to block pathogen binding or modulate aberrant signaling. For example, drugs like Maraviroc antagonize specific protein receptors, while others like Heparin mimic glycans to competitively inhibit binding. However, the ubiquitous nature and fundamental physiological roles of these surface molecules present significant challenges for drug development. Targeting these structures can lead to significant off-target effects or disruption of normal homeostatic signaling (Varki A, et al., 2015). Consequently, precision in targeting specific glycan motifs or protein epitopes is essential for therapeutic safety and efficacy.
Drugs targeting these components typically act as entry inhibitors by competitively binding to host receptors or pathogen ligands, or by enzymatically modifying the cell surface to prevent recognition and attachment.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Host cell surface glycans and proteins.